Accelerated Approvals Could Be Improved By Focusing On Benefit/Risk, Making Withdrawal Easier

Applying the expedited pathway in the context of a preliminary benefit/risk assessment, rather than focusing solely on predictive surrogate or intermediate clinical endpoints, would give the US FDA more flexibility, Friends of Cancer Research working group says in a new white paper.

the waiter cleaning the table in a outdoor cafe. He collects dirty dishes in a tray.
Giving US FDA the ability to easily clear the table of an accelerated approval drug that fails to confirm clinical benefit is proposed in a new white paper. • Source: Shutterstock

The US Food and Drug Administration’s accelerated approval program could be improved by reframing its focus on a drug’s benefit/risk profile rather than the effect on a surrogate endpoint.

Consideration also should be given to having sponsors resubmit for continued approval, rather than putting the onus on the FDA...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Approval Standards

More from Pathways & Standards